What is Virax Biolabs?
Virax Biolabs Group operates as a specialized biotechnology entity focused on the development of advanced T cell-based immune profiling and in vitro diagnostic technologies. The company addresses the growing demand for sophisticated tools to detect viral and immune-mediated diseases, providing essential immunology research assays and laboratory reagents. Their core competency lies in the creation of diagnostic platforms that facilitate the identification of adaptive immune responses, chronic inflammation, and the complexities associated with post-acute infection syndromes, including Long COVID. By bridging the gap between fundamental immunological research and clinical diagnostic application, the company serves as a vital partner for research institutions and healthcare providers seeking to understand and manage complex immune-mediated conditions.
How much funding has Virax Biolabs raised?
Virax Biolabs has raised a total of $14.1M across 3 funding rounds:
Stock Offering
$6.8M
Share Placement
$4M
Stock/Share Issuance
$3.3M
Stock Issuance/Offering (2022): $6.8M, investors not publicly disclosed
Share Placement (2023): $4M, investors not publicly disclosed
Stock/Share Issuance (2026): $3.3M, investors not publicly disclosed
Key Investors in Virax Biolabs
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Virax Biolabs?
Looking ahead, the strategic deployment of the $3.3M capital will likely focus on the commercialization of its diagnostic pipeline and the expansion of its global footprint. With a clear mandate to enhance its T cell-based diagnostic offerings, Virax Biolabs Group is expected to prioritize clinical validation studies and the scaling of its manufacturing infrastructure. The company's roadmap suggests a transition from research-heavy development to broader market penetration, aiming to establish its diagnostic platforms as the standard for monitoring immune-mediated diseases. As the firm continues to refine its technological stack, it remains a key player to watch for potential partnerships and further advancements in the field of precision immunology.
See full Virax Biolabs company page
